GM Advisory Group LLC Has $350,000 Stock Holdings in Zoetis Inc. (NYSE:ZTS)

GM Advisory Group LLC grew its stake in Zoetis Inc. (NYSE:ZTS) by 13.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,149 shares of the company’s stock after purchasing an additional 250 shares during the period. GM Advisory Group LLC’s holdings in Zoetis were worth $350,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Howard Capital Management Group LLC grew its holdings in shares of Zoetis by 0.8% in the 3rd quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company’s stock worth $20,489,000 after purchasing an additional 883 shares during the last quarter. Principal Financial Group Inc. raised its stake in shares of Zoetis by 17.3% in the third quarter. Principal Financial Group Inc. now owns 2,377,403 shares of the company’s stock valued at $464,497,000 after acquiring an additional 351,372 shares during the last quarter. Pathstone Holdings LLC boosted its holdings in shares of Zoetis by 0.5% in the 3rd quarter. Pathstone Holdings LLC now owns 60,660 shares of the company’s stock worth $11,852,000 after acquiring an additional 310 shares in the last quarter. Caprock Group LLC grew its position in Zoetis by 7.3% during the 3rd quarter. Caprock Group LLC now owns 11,984 shares of the company’s stock worth $2,342,000 after acquiring an additional 811 shares during the last quarter. Finally, West Family Investments Inc. acquired a new stake in Zoetis during the 3rd quarter valued at $253,000. Institutional investors own 92.80% of the company’s stock.

Insider Buying and Selling

In related news, Director Willie M. Reed sold 1,210 shares of the firm’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now owns 11,245 shares of the company’s stock, valued at approximately $1,868,244.30. This trade represents a 9.71 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the transaction, the executive vice president now directly owns 15,781 shares of the company’s stock, valued at approximately $2,682,770. The trade was a 2.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,862 shares of company stock valued at $312,254 in the last 90 days. 0.16% of the stock is owned by insiders.

Zoetis Price Performance

ZTS opened at $163.76 on Thursday. The company has a fifty day moving average price of $166.81 and a two-hundred day moving average price of $175.75. The firm has a market capitalization of $73.33 billion, a PE ratio of 29.94, a P/E/G ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.33. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. As a group, analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.22%. Zoetis’s dividend payout ratio is 36.56%.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of recent analyst reports. Barclays boosted their price objective on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. Morgan Stanley decreased their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Piper Sandler boosted their target price on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research note on Thursday, February 27th. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Leerink Partners assumed coverage on shares of Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective for the company. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $215.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.